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Serum proteomics of active 
tuberculosis patients and contacts 
reveals unique processes activated 
during Mycobacterium tuberculosis 
infection
Jesús Mateos  1*, olivia estévez2, África González-fernández2, Luis Anibarro2,3,4, 
Ángeles pallarés3, Rajko Reljic5, tufária Mussá6,7, cremildo Gomes-Maueia6, 
Artur nguilichane8, José M. Gallardo1, isabel Medina1 & Mónica carrera1*
Tuberculosis (TB) is the most lethal infection among infectious diseases. The specific aim of this 
study was to establish panels of serum protein biomarkers representative of active tB patients and 
their household contacts who were either infected (LtBi) or uninfected (eMi-tB Discovery cohort, 
Pontevedra Region, Spain). A TMT (Tamdem mass tags) 10plex-based quantitative proteomics study 
was performed in quintuplicate containing a total of 15 individual serum samples per group. Peptides 
were analyzed in an Lc-orbitrap elite platform, and raw data were processed using proteome 
Discoverer 2.1. A total of 418 proteins were quantified. The specific protein signature of active 
tB patients was characterized by an accumulation of proteins related to complement activation, 
inflammation and modulation of immune response and also by a decrease of a small subset of proteins, 
including apolipoprotein A and serotransferrin, indicating the importance of lipid transport and iron 
assimilation in the progression of the disease. This signature was verified by the targeted measurement 
of selected candidates in a second cohort (EMI-TB Verification Cohort, Maputo Region, Mozambique) 
by ELISA and nephelometry techniques. These findings will aid our understanding of the complex 
metabolic processes associated with tB progression from LtBi to active disease.
Tuberculosis (TB) is currently a global pandemic that kills approximately 1.3 million people worldwide each 
year1. Although the incidence of TB is decreasing each year, the rate of that decline is not high enough to accom-
plish the TB Global Strategy for the 2015–2035 period2,3. Mycobacterium tuberculosis (MTB) is the causal agent 
of the pulmonary TB4, which is air-transmitted by nasal/oral inhalation of aerosol droplets carrying the pathogen 
from an active TB patient to a healthy individual usually through coughing or sneezing5. Small droplets that are 
able to reach the lower lung induce formation of a granuloma6, which is a host-defensive structure providing, a 
fibrotic physical barrier between the infected and the healthy neighboring tissues7. Latently infected individuals 
(LTBI) represent roughly a quarter of the global population8. Tuberculin Skin Test (TST) and Interferon-Gamma 
Release Assay (IGRA) are commonly used for diagnosis9,10 of LTBI individuals. Although they cannot infect a 
healthy person, MTB activation occurs in roughly 10% of cases due to recurrent infections or a compromised 
immune system in the host11.
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The safest and most cost-effective way to fight against infectious diseases is vaccination12. TB and other 
poverty-related and neglected infectious diseases still lack effective vaccines to protect the entire population13. 
BCG (Bacillus Calmette-Guerin), the only licensed vaccine currently in use against TB, was developed eighty 
years ago and displays an efficacy of 80% or more in children under 4 years old14. However, the efficacy of BCG 
in adolescents and adults is variable, 0 to 80% depending on the geographical region15. The TB Global Strategy 
for the period of 2015–2035 draws special attention to the urgent need to develop a new, more efficient vaccine 
against TB16,17. Efforts are being made in different directions. While some research strategies have focused on 
boosting the existing BCG vaccine18 or exploring the use of new BCG strains19, others are focused on developing 
a mucosal vaccine, as is the case with the Horizon2020 EMI-TB consortium20,21.
Proteomics has been used in the last decade as a tool to globally analyze, at the protein level, cellular and 
whole-organism processes related to disease and its progression. Proteomic profiling allows the elucidation of 
connections between various cellular pathways and thus complements both the genomics and traditional bio-
chemical approaches. Several studies have focused on the MTB proteome, all of which were recently reviewed22. 
Alternatively, for the study of the molecular basis of health and disease, biological fluids from patients and con-
trols are a reliable source for the identification of protein markers23. Thanks to the extensive and continuous 
progress of analytical proteomics and because of the emergence of Mass Spectrometry-based techniques that 
facilitate the identification quantification and characterization of proteins, proteomics is expected to be, in the 
near future, the tool of choice for diagnosing patients and searching for therapeutic biomarkers24,25.
In the present study our focus was on identifying the specific protein signatures in sera of active TB patients 
and their contacts, including latently infected (LTBI) and uninfected contacts.
Experimental Procedures
patient selection and database management. Collection (discovery cohort) of samples from TB 
patients and their contacts (LTBI and uninfected) started in Pontevedra (Spain) on September 2015, within the 
framework of the EMI-TB project (Eliciting Mucosal Immunity to Tuberculosis) following previously established 
clinical criteria26. Briefly, patients were diagnosed using the highest standards for clinical TB research, includ-
ing tuberculin skin test (TST) and/or the Quantiferon-TB-Gold test (QFT) and again after 8–12 weeks after 
the last possible exposure to the index case if the first test was negative. Additionally, chest radiographies were 
done to exclude active TB patients from the LTBI group. Lowenstein-Jensen and Colletsos culture were done for 
all TB-diagnosed patients. The study was approved by the Spanish National Bioethics committee (Project ID: 
643558). Exclusion criteria were age <18 y, co-infection with the human immunodeficiency virus (HIV), any 
other immunossuppresive medical condition or concomitant use of immunossuppresive drugs. Patients with pre-
vious TB or LTBI were also excluded for the study. Serum samples were collected right after final diagnosys and 
before commencement of the anti-TB drug treatment. The datasets were analysed in blind fashion using codes 
and keeping the anonymity of the volunteers. Summary of the demographic data considered relevant to the study 
is shown in Table 1. Informed consent was obtained, and all patients and contacts received a detailed explanation 
of the project and its objectives, as well as the ensurance of the confidentiality.
In parallel, and also under the framework of the EMI-TB project, samples from TB patients (verification 
cohort) and their contacts (LTBI and uninfected) were also collected in the Maputo Region (Mozambique) using 
the same standard operating procedures (SOPs). The study was approved by the Mozambican National Bioethics 
committee (IRB:00002657; ID: 298/CNBS/15).
Additionally, all the experimental procedures described in this section were performed in accordance with 
relevant guidelines and regulations (both national and the EU).
Sample collection and storage of quantitative shotgun proteomics samples. EDTA (ethylene 
diamine tetra acetic acid) blood samples (40 mL) from each participant were obtained by the TB unit and imme-
diately transferred to the University of Vigo for processing. During the whole sample collection period the same 
SOP (Standard Operational Procedure), based on the recommendations of the Human Proteome Organization 
(HUPO), was applied. Once obtained, the serum samples were distributed into 1000 μL aliquots (Protein LoBind 





(mean ±SD)* BCG vaccination MTB culture
Active TB patient (n = 26) Female (15.4%), male (84.6%) 41.3 ± 13.9 n.a.
Yes: 15.4% (n = 4)
No: 84.6% (n = 22)
Positive: 100% (n = 26) 
Negative: 0% (n = 0)
LTBI contact (n = 29) Female (41.3%), male (58.7%) 47.4 ± 14.7 10.9 ± 2.6
Yes: 27,6% (n = 8)
No: 72.4% (n = 21) n.a.
Uninfected contact (n = 44) Female (52.3%), male (47.7%) 40.0 ± 15.2 9.6 ± 2.3
Yes: 32.8% (n = 14)
No: 68.2% (n = 30) n.a.
Table 1. Demographic summary of the patients included in the EMI-TB shotgun study cohort (Pontevedra, 
Spain). *“Contact Score” was assigned to the contacts following this criteria: acid-fast bacilli (AFB) microscopy 
index: from 0 to 4; cavitary X-rays: No = 0, Yes = 1; contact: No = 0, Yes = 1; hours of exposure/day: 0–3 hours: 
1, 4–7 hours: 2, 8–11 hours: 3, ≥ 12 hours: 4; type of exposure: Outdoors= 0.25, Different room: 1, As a bar: 2, 
As a class: 2.5, As an office: 3, As a room or car: 4; weeks in contact with Index Case: <12 weeks: 0, ≥ 12 weeks: 
1; sleeps in the same room: No = 0, Yes = 1; first-degree family relationship: No = 0, Yes = 1.
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protein preparation for tMt labeling. Total protein in the serum samples was precipitated by the addi-
tion of six volumes of cold acetone and incubated overnight at −20 °C. After centrifugation, the dried protein pel-
let was resuspended in 0.1 M TEAB buffer solution (Triethyl ammonium bicarbonate: Stock solution: 1 M). The 
protein concentration was measured by the bicinchoninic acid (BCA) assay. The protein integrity was confirmed 
in 1 µg aliquots by SDS-PAGE and silver staining. Samples with protein degradation were detected and discarded 
from the proteomic analysis.
Experimental design and statistical rationale. For the shotgun study, we analyzed individual serum 
samples rather than pools and later applied a robust statistical analysis of quantification ratios (Kruskal-Wallis). 
For this reason, we increased the number of TMT 10plex labels to five (Table 2). Three active TB patients (chan-
nels 126, 127 N and 127 C), three infected LTBI contacts (channels 128 N, 128 C and 129 N), three uninfected 
contacts (channels 129 C, 130 N and 130 C), making a total of 45 individual samples. One standard mix sample 
were included within each TMT experiment, prepared by mixing equal amounts of proteins for the nine samples 
included (channel 131).
TMT 10plex labeling. Samples were selected for the quantitative proteomics study according to their pro-
tein concentration and integrity. Labelling and fractionation of the protein samples were done as previously 
described27. Briefly, 100 µg of each individual sample was resuspended in a final volume of 100 µL of 0.1 M TEAB 
buffer solution, reduced/alkylated and digested with trypsin for 16 h at 37 °C. Labeling with TMT 10plex reagents 
(Thermo Fisher Scientific, San Jose, CA, US) was performed following the manufacturer’s indications.
peptide fractionation by high-pH reversed phase. Dried aliquots of 100 µg were reconstituted in 
300 µL of trifluoroacetic acid (TFA) and the peptides were fractionated using the High-pH Reversed Phase 
Fractionation Kit (Thermo Fisher Scientific) following the manufacturer’s instructions. The peptide concentra-
tion in the resulting eight fractions was determined using the Quantitative Colorimetric Peptide Assay (Thermo 
Fisher Scientific).
Lc analysis and orbitrap-elite settings. One microgram of each fraction was injected and analyzed by 
LC-MS/MS using a Proxeon EASY-nLC II liquid chromatography system (Thermo Fisher Scientific) coupled to 
an LTQ-Orbitrap Elite (Thermo Fisher Scientific). Separation of the peptides was performed on an RP column 
(EASY-Spray column, 50 cm × 75 μm ID, PepMap C18, 2 μm particles, 100 Å pore size, Thermo Fisher Scientific) 
with a 10 mm precolumn (Accucore XL C18, Thermo Fisher Scientific) using 0.1% formic acid (mobile phase A) 
and 98% ACN with 0.1% formic acid (mobile phase B). A 240 min linear gradient from 5 to 35% B was applied at 
a flow rate of 300 nL per min. Ionization was performed in an NSI source using a spray voltage of 1.95 kV and a 
capillary temperature of 275 °C. The peptides were analyzed in positive mode (1 μscan; 400–1600 amu), followed 
by 10 data-dependent HCD (high-energy collision dissociation) MS/MS scans (1 μscans), using a normalized col-
lision energy of 38% at a resolution of 30,000 and an isolation width of 1.5 amu. Dynamic exclusion was enabled 
with a repeat count of 1, a repeat duration of 30 s, a duration of the exclusion of 80 s, and a relative exclusion width 
of 10 ppm. Unassigned charged ions were excluded from the analysis.
TMT 1 
Serum
SAMPLE PO-20 PO-28 PO-38 PO-24 PO-27 PO-36 PO-21 PO-26 PO-44 Standard
Group TB TB TB LTBI LTBI LTBI Uninfected Uninfected Uninfected Mix
TMT-Label 126 127 N 127 C 128 N 128 C 129 N 129 C 130 N 130 C 131
BCG vaccination No No Yes No Yes Yes No No No n.a.
TMT 2 
Serum
SAMPLE PO-16 PO-40 PO-51 PO-30 PO-41 PO-54 PO-34 PO-57 PO-65 Standard
Group TB TB TB LTBI LTBI LTBI Uninfected Uninfected Uninfected Mix
TMT-Label 126 127 N 127 C 128 N 128 C 129 N 129 C 130 N 130 C 131
BCG vaccination No No No No No No No No No n.a.
TMT 3 
Serum
SAMPLE PO-32 PO-63 PO-88 PO-31 PO-42 PO-55 PO-68 PO-73 PO-72 Standard
Group TB TB TB LTBI LTBI LTBI Uninfected Uninfected Uninfected Mix
TMT-Label 126 127 N 127 C 128 N 128 C 129 N 129 C 130 N 130 C 131
BCG vaccination Yes No No No Yes No No No No n.a.
TMT 4 
Serum
SAMPLE PO-76 PO-90 PO-53 PO-66 PO-101 PO-87 PO-75 PO-77 PO-79 Standard
Group TB TB TB LTBI LTBI LTBI Uninfected Uninfected Uninfected Mix
TMT-Label 126 127 N 127 C 128 N 128 C 129 N 129 C 130 N 130 C 131
BCG vaccination No No No No No Yes No Yes No n.a.
TMT 5 
Serum
SAMPLE PO-102 PO-67 PO-29 PO-80 PO-92 PO-86 PO-82 PO-72 PO-78 Standard
Group TB TB TB LTBI LTBI LTBI Uninfected Uninfected Uninfected Mix
TMT-Label 126 127 N 127 C 128 N 128 C 129 N 129 C 130 N 130 C 131
BCG vaccination No Yes No Yes Yes No Yes No No n.a.
Table 2. Individual serum samples used in the EMI-TB shotgun study.
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Mass spectrometry data processing. Xcalibur 3.1 software (Thermo Fisher Scientific) was used for data 
acquisition, raw file generation, inspection of the chromatography profile and confirmation of the labeling of 
the peptides. After that, protein identification and quantification were performed using Proteome Discoverer 
2.1 software (Thermo Fisher Scientific). Peak lists were generated with a precursor signal-to-noise ratio of 1.5, 
and default settings were used to search the latest Human UniProtKB/SwissProt Release (2018_10 with 551,681 
entries) with the Sequest algorithm. The enzyme specificity was set to trypsin, and one missed cleavage was tol-
erated. TMT-labeling and carbamidomethylation of cysteines were set as fixed modifications, whereas oxidation 
of methionines and N-terminal acetylation were set as variable modifications. The precursor ion mass tolerance 
was set to 7 ppm, and the product ion mass tolerance was set to 0.06 Da. A decoy database search was performed 
to determine the peptide false discovery rate (FDR) with the Target Decoy PSM (peptide-spectrum matches) 
Validator Module. Quantification was performed using a Quantification Module, and normalization was per-
formed against the total peptide amount. A 1% peptide FDR threshold was applied.
Samples were categorized by the patient type (TB, LTBI and uninfected contacts and internal standard). 
Quantification jobs were alternatively launched using a) the patient type option for the global analysis and b) the 
individual ratios option for the nonparametric statistical analysis.
Protein identification and quantification. For the Venn diagram representation, a list of proteins from 
each TMT experiment was quantified and at least one unique peptide was loaded in the InteractiVenn tool28. For 
ratio dispersion representation, all the ratios for all the proteins quantified in the five TMT experiments were 
extracted from the Proteome Discoverer 2.1 software using the “export to Excel” option, and dispersion diagrams 
were performed using XLSTAT software.
Statistical analysis of the TMT quantification ratios. Only proteins identified and quantified in the 
five TMT experiments were considered for statistical analysis. Briefly, the protein ratios (45 for each comparison; 
9 ratios per TMT experiment, 5 TMT experiments) were imported into R commander console (statistical package 
included in R 3.5.1 software) and represented in box diagrams. For each protein, data were used to analyze the 
differences between the three studied ratios (45 ratios uninfected/LTBI, 45 ratios uninfected/TB and 45 ratios TB/
LTBI) by applying a Kruskal-Wallis test, since we observed that the quantification ratios did not follow a normal 
distribution. Differences in the modulation were considered significant when p-value ≤ 0.001.
The final list (UniProt accession number) of significantly modulated proteins was analyzed using String 10.1 
software for the determination of pathways and biological processes modulated in each group of participants.
Figure 1. Summary of the quantitative shotgun proteomic study. Venn diagram representation of the five 
TMT experiments (A). A total of 418 proteins were identified and quantified with at least one unique peptide 
in the whole study. 154 of them were common for the five TMT experiments. Dispersion diagrams for the 154 
common proteins (B–D) representing the mean of the log2 ratio and the standard error of the mean (SEM).
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eLiSA of selected proteins. Serum levels of selected proteins were measured in the verification cohort 
using the following ELISA kits (Abcam): ab99995 (CRP), ab108852 (A1AGP1), ab219048 (HPT), ab108911 
(TRFE) and ab202405 (KLK1B). Briefly, serum samples (twenty-one active TB patients and fifteen LTBI con-
tacts) were diluted accordingly in the supplied sample diluent, and immunodetection was performed follow-
ing the manufacturer’s instructions. Absorbance was recorded in triplicate at 450 nm in a Multiskan GO Plate 
Reader (Thermo Fisher Scientific). Statistical analysis (Kruskal-Wallis) and diagrams were performed using R 
commander console and GraphPad software.
Nephelometry analysis of APOA1 in serum samples. APOA1 serum levels were measured in the ver-
ification cohort using an ImmageTM nephelometer (Beckman-Coulter) and the corresponding APOA1 reagent 
kit (#4464110, Beckman Instruments, Inc.) following the manufacturer’s instructions. Statistical analysis and 
diagrams were performed using R commander console and GraphPad software.
Receiver operating characteristic (Roc) analysis of the targeted analysis of selected pro-
teins. The diagnostic accuracy of the six selected proteins were assessed by the receiver operator characteris-
tics (ROC) curve analysis. The cut-off values for each parameter were determined by the highest Youden Index 
in order to maximize the sensitivity and specificity of the test. Statistical analysis was performed using GraphPad 
Prism version 6.0 for Windows (GraphPad Software; CA, USA) and IBM SPSS version 23 for windows (SPSS Inc., 
Chicago, Ill., USA).
Results
Protein identification and quantification. Proteomic datasets were deposited in the MassIVE repos-
itory (www.massive.ucsd.edu). Raw and processed files (SERUM_DATA_FILES_EMI_TB_PROTEOMICS; 
#MSV000083645) are public and freely accessible. Figure 1 represents the global identification results. The num-
ber of proteins identified in each TMT with at least one unique peptide range from 293 in TMT1 to 225 in TMT2 
(Fig. 1A), whereas a total of 154 proteins were identified and quantified in the five TMT experiments with at least 
one unique peptide, 147 of them with at least two unique peptides (Fig. 2A and Supplementary Information). 
Dispersion diagrams of the quantification ratios show slight differences between uninfected versus LTBI partici-
pants (Fig. 1B) and more evident differences between active TB patients versus both uninfected and LTBI contacts 
(Fig. 1C,D).
Figure 2. Summary of the number of unique peptides quantified per protein (A). Ninety-five percent of the 
proteins were quantified with at least two unique peptides. Volcano-plot representations of the statistical 
analysis of the quantification ratios. A specific proteomic signature is detected when comparing active TB 
patients versus both LTBI (B) and uninfected (C) contacts. No apparent specific signature is detected when 
comparing uninfected versus LTBI contacts (D). Significance is considered when p-value ≤ 0.001.
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Specific serum proteomic signature of active TB patients, LTBI contacts and uninfected con-
tacts. A nonparametric Kruskal-Wallis statistical analysis was applied to the quantification ratios for all the 
proteins. Volcano-plot representations are shown in Fig. 2. Differences were detected between active TB patients 
and both uninfected and LTBI contacts (Fig. 2A,B), whereas no detectable differences were detected when com-
paring LTBI versus uninfected contacts.
Examples of proteins that accumulated in the serum of active TB patients include C-reactive protein (CRP), 
haptoglobin (HPT) alpha-1-acid glycoprotein 1 (A1AGP1), complement component C9 (C9), neutrophil defen-
sin 1 (DEF1) and serum amyloid P component (SAA2–4). Volcano-plot representation of the quantification ratios 
showed no apparent differences in the serum protein content when comparing LTBI versus uninfected contacts.
In contrast, proteins such as apolipoprotein A (APOA1 and 2), serotransferrin (TRFE) and plasma kallikrein 
(KLK1B) were decreased in the serum of active TB patients (Fig. 2A,B). Similarly, the proteins that were dimin-
ished in the serum of active TB patients presented no differences when comparing LTBI versus uninfected con-
tacts (Fig. 2).
pathway and interaction analysis of modulated proteins. String 10.1 analysis showed a strong inter-
action network between the set of modulated proteins (Fig. 3A). Enrichment analyses by biological processes, cell 
compartment and SMART domains were performed (Fig. 3B–D), showing that most of the proteins modulated 
in active TB patients are secreted and play roles in complement activation, acute-phase response and modulation 
of inflammation. Box plot diagrams of the quantification ratios show that this set of proteins is specifically modu-
lated in the serum of active TB patients, while no differences are detected when comparing LTBI and uninfected 
contacts (Figs. 4 and 5).
targeted measurement of selected candidates in serum samples. ELISA and nephelometry tech-
niques were used for verification in a second cohort due to the clinical relevance of identified proteins. A1AGP1, 
CRP and HPT were selected as proteins overrepresented in active TB patients versus both LTBI and uninfected 
contacts, whereas KLKB1, TRFE and APOA were selected as proteins diminished in active TB patients ver-
sus both LTBI and uninfected contacts. Statistical analysis showed similar results to those obtained for the six 
proteins in the shotgun proteomics phase (Fig. 6A). Significant differences (p-value ≤0.01) were observed for 
A1AGP1, CRP, TRFE and APOA. Less significant differences (p-value ≤0.05) were obtained for KLKB1, and no 
significant differences (p-value = 0.08) were observed for HPT.
Figure 3. Interaction and pathway analysis of the proteins detected as modulated in active TB patients. String 
10.1 analysis show a strong interaction network (A) between those proteins. Statistical pathway analysis 
(B–D) show that most of the proteins play roles in defense against pathogens, complement activation and 
inflammation.
7Scientific RepoRtS |         (2020) 10:3844  | https://doi.org/10.1038/s41598-020-60753-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
Receiver Operating Characteristic (ROC) analysis showed that five out of the six proteins present AUC (area 
under the curve) values higher than 0.7 (Fig. 6B). Two of them, CRP (AUC= 0.92) and TRFE (AUC= 0.83), pre-
sented the best balance between sensitivity and specificity, as revealed by Youden index analysis (Fig. 6C).
Discussion
The host innate and acquired immune processes activated during MTB infection and disease progression are still 
not fully understood. Biomarker discovery in biological fluids using high-resolution proteomics allows research-
ers to identify the modulation of cellular pathways when comparing different disease progression states. In the 
previous work, we focused on the analysis of nasal/oral fluid samples to obtain a deeper understanding of the 
innate immune processes implicated in resistance to the initial MTB infection27. In the present study, by analyz-
ing serum samples of active TB patients and their contacts, our aim was to focus on the mechanisms activated 
systematically in the host during the progression of the disease.
A total of 418 serum proteins were quantified in our study. At first, it might seem that the number of total 
quantified proteins using our approach was not high, but this result is typical of non-depleted serum samples. 
Depletion of abundant proteins using commercially available antibody-coated LC columns or cartridges29 as well 
as other approaches, such as those based on the use of combinatorial hexapeptide ligand libraries30, enables a 
higher coverage of the serum and plasma proteome in mass spectrometry-based studies but at the cost of losing 
information from highly abundant proteins and protein complexes. In a previous multilaboratory experiment 
(Proteored Multicenter Experiment 6), several groups were able to identify more than one hundred different 
proteins in the “bound” fraction of a immune-depleted serum sample with a commercial column supposed to 
bind only the 20 most abundant serum proteins31. In the present study, we took the view that information com-
ing from those abundant proteins is important and should be also analysed. In future studies, we also think 
that a larger coverage of the serum proteome could be obtained by increasing the level of peptide fractionation, 
using off-gel-based techniques32. However, the number of proteins quantified in the present study are in con-
cordance with very recent serum-based studies. Using MALDI-TOF mass spectrometry (no tryptic digestion 
and no fragmentation) Zhang et al.33 found 236 serum “protein peaks” differentially expressed between patients 
with Intestinal Tuberculosis (ITB) and Crohn´s Disease (CD). In another study by Arya et al.34, 132 and 68 serum 
extracellular vesicle (EVs) proteins from active TB patients were identified when compare to non-tuberculosis 
and healthy patients. The number of identified proteins were higher (more than seven hundred with at least one 
unique peptide) in the study by Chen et al.35 by analyzing immune-depleted serum samples. Finally, Liu et al.36 
were able to identify one thousand proteins in plasma samples using label-free quantification of severe and mild 
TB patients versus healthy individuals with no exposure to MTB.
Figure 4. Box-plot representation of selected proteins that are detected as over-represented in the serum of 
active TB patients versus both LTBI and uninfected contacts but are not modulated when comparing uninfected 
versus LTBI contacts. ****p-value ≤ 0.00001; ***p-value ≤ 0.001.
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Regarding protein identification and quantification, we obtained good reproducibility when comparing the 
data from five different TMT experiments. A total of 154 proteins are common to the five biological replicates and 
147 of them were quantified with at least two unique peptides (Fig. 2A and supplementary info). The standard 
error of the mean (SEM) of the ratios is low for most of them (Fig. 1B–D).
Kruskal-Wallis test was applied to detect significantly modulated proteins when comparing different progres-
sion states of the disease (Fig. 2B–D). Uninfected contacts remained free of MTB infection despite high degree 
exposure to an active TB patient (Table 1). We have recently identified some components of the innate immune 
response that specifically accumulate in the sputum of these uninfected individuals when compared with LTBI 
contacts27, indicating the importance of nasal/oral secretions as a first barrier to fighting the initial entry of MTB. 
In the present study, using the same approach, we were unable to detect any serum protein significantly accu-
mulated in uninfected contacts versus LTBI contacts (Fig. 2D). In contrast, a set of proteins were significantly 
accumulated in active TB patients versus both LTBI and uninfected contacts (Fig. 2B,C).
Interaction network and pathway analysis showed that the specific protein signature of active TB patients was 
characterized by an accumulation of proteins related to complement activation, inflammation and modulation 
of the immune response (Fig. 3). Individual box plot diagrams representing the three kind of ratios show the 
specificity for modulated proteins (Figs. 4 and 5). For instance, proteins, such as C-reactive protein, haptoglobin 
and alpha-1 acid glycoprotein- 1 and −2 (ORM-1 and -2), were specifically accumulated in active TB patients, 
whereas no differences were detected when comparing LTBI and uninfected contacts (Fig. 4). All these proteins 
were previously identified as accumulated in serum samples of TB patients with antibody-based techniques37,38, 
by label-free mass spectrometry36, and more recently in saliva and sputum samples27. To the best of our knowl-
edge, other proteins, such as neutrophil defensin 1 and lysozyme C, have not been previously described as being 
accumulated in the serum of active TB patients.
Furthermore, a decrease in a small subset of proteins, including apolipoproteins A1, A2 and A4, serotrans-
ferrin and plasma kallikrein, was revealed as characteristic of active TB patients (Fig. 5). The ApoA complex is a 
central component of high density lipoproteins (HDL) and is one of the main components responsible for lipid 
transport from tissues to the liver39. A decrease in ApoA1 was associated with HDL deficiency type 2 or hyper-
cholesterolemia more than two decades ago40; interestingly, a decrease in ApoA1 has been more recently reported 
to cause an impairment of the immune response against TB41. In relation to this finding, ApoA was detected to 
be increased during rifampicin treatment of active TB in humans42 and formed a complex with isoniazid during 
the treatment in a TB mouse model43. At this point, it is important to remark that the serum samples used in the 
present study were collected before patients underwent anti-TB treatment, so the serum levels of ApoA1 are not 
Figure 5. Box-plot representation of selected proteins that are detected as decreased in the serum of active TB 
patients versus both LTBI and uninfected contacts but are not modulated when comparing uninfected versus 
LTBI contacts. ****p-value ≤ 0.00001; ***p-value ≤ 0.001.
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influenced by the uptake of anti-TB or any other drugs. This finding is in concordance with a previous quanti-
tative proteomics study in which ApoA was found to be increased after anti-TB drug treatment in cured versus 
untreated tuberculosis patients44, thus strongly indicating that rifampicin/isoniazid treatment increases the serum 
levels of this protein. A possibility is that LTBI contacts with decreased levels of ApoA1 could be more susceptible 
to developing active TB than those presenting normal levels of this protein (Fig. 7). Further investigations are 
needed to explore the putative implications of this result in the treatment of the disease.
In addition, iron assimilation of MTB from the host has been revealed as a key pathway for the progression 
of the disease45. Specifically, MTB acquisition of iron from serotransferrin has been reported to be decreased by 
IFN-gamma treatment46. Patients with hemochromatosis, also known as iron overload, have been previously 
associated with more severe TB disease47. The decrease in serotransferrin levels as a host mechanism of defense 
against TB progression via iron deprivation represents an attractive possibility to be investigated in the future.
Plasma kallikreins are a group of serine proteases involved in inflammation and autoimmune response 
processes48,49. KLK1 was previously described by genome-wide transcriptome profiling as downregulated in 
MTB-stimulated peripheral blood mononuclear cells (PBMCs) from patients with TB; thus, KLK1 was previously 
used in combination with other markers to discriminate active TB patients from LTBI individuals and healthy 
controls50.
Figure 6. Targeted measurement of the serum levels of selected candidates (three over-represented and three 
decreased in active TB patients) in an independent cohort (verification cohort, Maputo region, Mozambique). 
Significant (p-val≤ 0.05) modulation is detected for five out of the six proteins (A). ROC (B) and Youden index 
(C) analysis was done for the six targets to investigate their discriminatory potential between active TB patients 
and latently infected contacts.
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Verification of selected proteins in a second cohort was performed using antibody-based targeted techniques 
since these approaches are still considered the gold standard for clinical validation despite the promising develop-
ment of multiplexing immunoassays51. The targeted measurement of the selected proteins was in agreement with 
the shotgun proteomic data, and five out of the six proteins were detected as significantly modulated in active TB 
patients versus LTBI contacts (Fig. 6A). ROC analysis showed that the serum levels of those five proteins could 
have a potential for discriminating between active TB and latent infected contacts. In particular, CRP and TRFE 
display a good balance between sensitivity and specificity (Fig. 6B,C and Supplementary Data 2). However, the 
putative discriminatory potential of those targets is still based on preliminary data and further investigation using 
bigger cohorts including other non-TB respiratory diseases are needed.
TB burden is especially dramatic in sub-Saharan countries52; Mozambique, as the country of origin in the sec-
ond cohort is from this region and, therefore, verification of the initial quantitative proteomics study in this sec-
ond group of participants from a distant geographical region increases the strength of our findings and suggests 
a common host-acquired immune response to TB. Recently, mass spectrometry has been used to study the effect 
of phosphorylation in mycobacterial proteins known to be involved in MTB virulence53. Although, MTB strain 
identification was not performed during patient diagnosis, it would be of interest to investigate whether or not 
different MTB strains possessing distinct pathogenicity traits promote similar defense mechanisms in the host.
We think that the findings presented in our study could have important implications for treating MTB and 
contribute to our understanding of the host defense mechanisms against TB. To summarize, lipid transport, iron 
assimilation acute-phase response and inflammation have all been identified as modulated pathways when com-
paring latent TB infection versus active TB disease (Fig. 7). We believe that these findings carry significant bio-
logical relevance and will help to better understand MTB pathogenesis and the host innate response, potentially 
aiding the rational vaccine design and testing for future studies.
Data availability
Raw and processed files (SERUM_DATA_FILES_EMI_TB_PROTEOMICS; #MSV000083645) and statistical 
analysis are publicly and freely accessible from the MassIVE Repository (www.massive.ucsd.edu).
Received: 23 July 2019; Accepted: 17 February 2020;
Published: xx xx xxxx
References
 1. Floyd, K., Glaziou, P., Zumla, A. & Raviglione, M. The global tuberculosis epidemic and progress in care, prevention, and research: 
an overview in year 3 of the End TB era. The Lancet Respiratory Medicine 6, 299–314, https://doi.org/10.1016/S2213-2600(18)30057-
2 (2018).
 2. Uplekar, M. & Raviglione, M. WHO’s End TB Strategy: From stopping to ending the global TB epidemic. Indian J Tuberc 62, 
196–199, https://doi.org/10.1016/j.ijtb.2015.11.001 (2015).
Figure 7. Schematic representation of the processes and proteins detected as modulated during the progression 
of the TB from a latent asymptomatic infection to an active disease. Proteins in blue are decreased in active TB 
patients whereas proteins in red are increased in this group versus both LTBI and uninfected contacts. Proteins 
in bold were also detected as significantly modulated in an independent cohort by targeted antibody-based 
techniques.
1 1Scientific RepoRtS |         (2020) 10:3844  | https://doi.org/10.1038/s41598-020-60753-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
 3. Lytras, T. & Kalkouni, O. The global tuberculosis epidemic: turning political will into concrete action. Journal of thoracic disease 10, 
S3149–S3152, https://doi.org/10.21037/jtd.2018.08.73 (2018).
 4. Sandgren, A. et al. Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis 16, 
204, https://doi.org/10.1186/s12879-016-1550-y (2016).
 5. Fennelly, K. P. et al. Cough-generated aerosols of Mycobacterium tuberculosis: a new method to study infectiousness. Am J Respir 
Crit Care Med 169, 604–609, https://doi.org/10.1164/rccm.200308-1101OC (2004).
 6. Via, L. E. et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76, 2333–2340, 
https://doi.org/10.1128/IAI.01515-07 (2008).
 7. Adams, D. O. The granulomatous inflammatory response. A review. Am J Pathol 84, 164–192 (1976).
 8. Houben, R. M. & Dodd, P. J. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. 
PLoS Med 13, e1002152, https://doi.org/10.1371/journal.pmed.1002152 (2016).
 9. Rao, M. et al. Latent TB Infection (LTBI) - Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma 
battleground. Int J Infect Dis 80S, S58–S61, https://doi.org/10.1016/j.ijid.2019.02.035 (2019).
 10. Rana, A., Thakur, S., Kumar, G. & Akhter, Y. Recent Trends in System-Scale Integrative Approaches for Discovering Protective 
Antigens Against Mycobacterial Pathogens. Front Genet 9, 572, https://doi.org/10.3389/fgene.2018.00572 (2018).
 11. Ahmad, S. Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clin Dev Immunol 2011, 
814943, https://doi.org/10.1155/2011/814943 (2011).
 12. Delany, I., Rappuoli, R. & De Gregorio, E. Vaccines for the 21st century. EMBO Mol Med 6, 708–720, https://doi.org/10.1002/
emmm.201403876 (2014).
 13. Bethony, J. M. et al. Vaccines to combat the neglected tropical diseases. Immunol Rev 239, 237–270, https://doi.org/10.1111/j.1600-
065X.2010.00976.x (2011).
 14. Hawn, T. R. et al. Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev 78, 650–671, https://doi.org/10.1128/
MMBR.00021-14 (2014).
 15. Roy, A. et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-
analysis. BMJ 349, g4643, https://doi.org/10.1136/bmj.g4643 (2014).
 16. Zumla, A. et al. The WHO 2014 global tuberculosis report–further to go. Lancet Glob Health 3, e10–12, https://doi.org/10.1016/
S2214-109X(14)70361-4 (2015).
 17. Weber, W. P. et al. The association of preoperative anemia and perioperative allogeneic blood transfusion with the risk of surgical site 
infection. Transfusion 49, 1964–1970, https://doi.org/10.1111/j.1537-2995.2009.02204.x (2009).
 18. Penn-Nicholson, A. et al. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy 
adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med 6, 287–298, https://doi.
org/10.1016/S2213-2600(18)30077-8 (2018).
 19. Nieuwenhuizen, N. E. & Kaufmann, S. H. E. Next-Generation Vaccines Based on Bacille Calmette-Guerin. Front Immunol 9, 121, 
https://doi.org/10.3389/fimmu.2018.00121 (2018).
 20. Stylianou, E. et al. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis 
infection in mice. Eur J Immunol 44, 440–449, https://doi.org/10.1002/eji.201343887 (2014).
 21. Diogo, G. R. & Reljic, R. Development of a new tuberculosis vaccine: is there value in the mucosal approach? Immunotherapy 6, 
1001–1013, https://doi.org/10.2217/imt.14.62 (2014).
 22. Banaei-Esfahani, A., Nicod, C., Aebersold, R. & Collins, B. C. Systems proteomics approaches to study bacterial pathogens: 
application to Mycobacterium tuberculosis. Curr Opin Microbiol 39, 64–72, https://doi.org/10.1016/j.mib.2017.09.013 (2017).
 23. Csosz, E. et al. Quantitative body fluid proteomics in medicine - A focus on minimal invasiveness. J Proteomics 153, 30–43, https://
doi.org/10.1016/j.jprot.2016.08.009 (2017).
 24. Legrain, P. et al. The human proteome project: current state and future direction. Mol Cell Proteomics 10, M111 009993, https://doi.
org/10.1074/mcp.M111.009993 (2011).
 25. Rai, A. J. et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for 
plasma proteome samples. Proteomics 5, 3262–3277, https://doi.org/10.1002/pmic.200401245 (2005).
 26. González-Martín, J. et al. [Consensus document on the diagnosis, treatment and prevention of tuberculosis]. Enferm Infecc Microbiol 
Clin 28, 297.e291–220, https://doi.org/10.1016/j.eimc.2010.02.006 (2010).
 27. Mateos, J. et al. High-resolution quantitative proteomics applied to the study of the specific protein signature in the sputum and 
saliva of active tuberculosis patients and their infected and uninfected contacts. J Proteomics 195, 41–52, https://doi.org/10.1016/j.
jprot.2019.01.010 (2019).
 28. Heberle, H., Meirelles, G. V., da Silva, F. R., Telles, G. P. & Minghim, R. InteractiVenn: a web-based tool for the analysis of sets 
through Venn diagrams. BMC Bioinformatics 16, 169, https://doi.org/10.1186/s12859-015-0611-3 (2015).
 29. Yadav, A. K. et al. A systematic analysis of eluted fraction of plasma post immunoaffinity depletion: implications in biomarker 
discovery. PLoS One 6, e24442, https://doi.org/10.1371/journal.pone.0024442 (2011).
 30. Li, S. et al. Digging More Missing Proteins Using an Enrichment Approach with ProteoMiner. J Proteome Res 16, 4330–4339, https://
doi.org/10.1021/acs.jproteome.7b00353 (2017).
 31. Asanov, K. et al. Multi-Site Assessment of ProteoRed Plasma Reference Sample for Benchmarking LC-MS Platform Performance. 
Journal of Biomolecular Techniques: JBT 22, S66–S67 (2011).
 32. Franchin, C., Pivato, M., Rattazzi, M., Arrigoni, G. & Millioni, R. OFFGEL fractionation of peptides: where really is your sample? J 
Chromatogr A 1355, 278–283, https://doi.org/10.1016/j.chroma.2014.05.077 (2014).
 33. Zhang, F. et al. Exploration of Serum Proteomic Profiling and Diagnostic Model That Differentiate Crohn’s Disease and Intestinal 
Tuberculosis. PLoS One 11, e0167109, https://doi.org/10.1371/journal.pone.0167109 (2016).
 34. Arya, R. et al. Serum Small Extracellular Vesicles Proteome of Tuberculosis Patients Demonstrated Deregulated Immune Response. 
Proteomics Clin Appl, e1900062, https://doi.org/10.1002/prca.201900062 (2019).
 35. Chen, C., Yan, T., Liu, L., Wang, J. & Jin, Q. Identification of a Novel Serum Biomarker for Tuberculosis Infection in Chinese HIV 
Patients by iTRAQ-Based Quantitative Proteomics. Front Microbiol 9, 330, https://doi.org/10.3389/fmicb.2018.00330 (2018).
 36. Liu, Q. et al. Proteomic profiling for plasma biomarkers of tuberculosis progression. Mol Med Rep 18, 1551–1559, https://doi.
org/10.3892/mmr.2018.9134 (2018).
 37. De Groote, M. A. et al. Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary 
Tuberculosis. J Clin Microbiol. https://doi.org/10.1128/JCM.00467-17 (2017).
 38. Phalane, K. G. et al. Differential expression of host biomarkers in saliva and serum samples from individuals with suspected 
pulmonary tuberculosis. Mediators Inflamm 2013, 981984, https://doi.org/10.1155/2013/981984 (2013).
 39. Pankhurst, G. et al. Characterization of specifically oxidized apolipoproteins in mildly oxidized high density lipoprotein. J Lipid Res 
44, 349–355, https://doi.org/10.1194/jlr.M200256-JLR200 (2003).
 40. Brooks-Wilson, A. et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22, 
336–345, https://doi.org/10.1038/11905 (1999).
 41. Martens, G. W. et al. Hypercholesterolemia impairs immunity to tuberculosis. Infect Immun 76, 3464–3472, https://doi.org/10.1128/
IAI.00037-08 (2008).
 42. Albanna, A. S., Bachmann, K., White, D., Valiquette, C. & Menzies, D. Serum lipids as biomarkers for therapeutic monitoring of 
latent tuberculosis infection. Eur Respir J 42, 547–550, https://doi.org/10.1183/09031936.00064713 (2013).
1 2Scientific RepoRtS |         (2020) 10:3844  | https://doi.org/10.1038/s41598-020-60753-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
 43. Sumenkova, D. V., Poliakov, L. M. & Panin, L. E. [Influence of isoniazid complex with A-I apolipoprotein on activity of lysosomal 
enzymes in mice with tuberculous inflammation model]. Eksp Klin Farmakol 75, 28–30 (2012).
 44. Wang, C. et al. Screening and identification of five serum proteins as novel potential biomarkers for cured pulmonary tuberculosis. 
Sci Rep 5, 15615, https://doi.org/10.1038/srep15615 (2015).
 45. Banerjee, S., Farhana, A., Ehtesham, N. Z. & Hasnain, S. E. Iron acquisition, assimilation and regulation in mycobacteria. Infect 
Genet Evol 11, 825–838, https://doi.org/10.1016/j.meegid.2011.02.016 (2011).
 46. Olakanmi, O., Schlesinger, L. S., Ahmed, A. & Britigan, B. E. Intraphagosomal Mycobacterium tuberculosis acquires iron from both 
extracellular transferrin and intracellular iron pools. Impact of interferon-gamma and hemochromatosis. J Biol Chem 277, 
49727–49734, https://doi.org/10.1074/jbc.M209768200 (2002).
 47. Abreu, R., Essler, L., Loy, A., Quinn, F. & Giri, P. Heparin inhibits intracellular Mycobacterium tuberculosis bacterial replication by 
reducing iron levels in human macrophages. Sci Rep 8, 7296, https://doi.org/10.1038/s41598-018-25480-y (2018).
 48. Sotiropoulou, G., Pampalakis, G. & Diamandis, E. P. Functional roles of human kallikrein-related peptidases. J Biol Chem 284, 
32989–32994, https://doi.org/10.1074/jbc.R109.027946 (2009).
 49. Liu, K. et al. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in 
mice and humans. J Clin Invest 119, 911–923, https://doi.org/10.1172/JCI36728 (2009).
 50. Pan, L. et al. Genome-wide transcriptional profiling identifies potential signatures in discriminating active tuberculosis from latent 
infection. Oncotarget 8, 112907–112916, https://doi.org/10.18632/oncotarget.22889 (2017).
 51. Tighe, P. J., Ryder, R. R., Todd, I. & Fairclough, L. C. ELISA in the multiplex era: potentials and pitfalls. Proteomics Clin Appl 9, 
406–422, https://doi.org/10.1002/prca.201400130 (2015).
 52. Soares, N. C., Bou, G. & Blackburn, J. M. Editorial: Proteomics of Microbial Human Pathogens. Front Microbiol 7, 1742, https://doi.
org/10.3389/fmicb.2016.01742 (2016).
 53. Calder, B., Albeldas, C., Blackburn, J. M. & Soares, N. C. Mass Spectrometry Offers Insight into the Role of Ser/Thr/Tyr 
Phosphorylation in the Mycobacteria. Front Microbiol 7, 141, https://doi.org/10.3389/fmicb.2016.00141 (2016).
Acknowledgements
We are very grateful for the specialized personnel of “Complexo Hospitalario Universitario de Pontevedra” 
(SERGAS), specially Alberto Peña and Laura Calviño, for collecting and processing samples and for the patients 
and their contacts for participating in the present study and their altruistic donation of serum samples. The 
picture of the granuloma was kindly provided by Carlos Álvarez-Álvarez (SERGAS). We also thank Lelia Pedrós 
and Josefa San José-Vega (Hospital Meixoeiro, Vigo, Pontevedra, Spain) for nephelometry measurements of 
ApoA. Shotgun data acquisition was performed by Manuel Marcos (Proteomics Facility, University of Vigo, 
CACTI, Vigo, Spain). CSIC (M.C.), CINBIO (A.G.F.), EMU (T. M.) and SGUL (R.R.) groups are part of the 
Eliciting Mucosal Immunity in Tuberculosis (EMI-TB) consortium. EMI-TB is a European Union Horizon2020-
funded action (Grant No. 643558) focused on selecting and developing a novel vaccine candidate for TB. We 
thank all the members of the EMI-TB, especially Elina Garet and Silvia Lorenzo-Abalde, for their collaboration 
and helpful discussions and suggestions.
Author contributions
J.M. and O.E. performed the experiments and analyzed data. L.A. and A.P., T.M., A.N. and C.G.M. managed 
the patient cohorts and collected/distributed serum samples. J.M. and M.C. designed the study, analyzed data, 
processed data, prepared figures and wrote the manuscript. M.C., R.R., L.A., A.G.F., I.M. and J.M.G. got funding 
and critically reviewed the manuscript.
competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-60753-5.
Correspondence and requests for materials should be addressed to J.M. or M.C.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
